{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:36:08Z","timestamp":1791045368366,"version":"4.1.0"},"reference-count":148,"publisher":"European Respiratory Society (ERS)","issue":"161","license":[{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2021,5,4]]},"published-print":{"date-parts":[[2021,9,30]]},"abstract":"<jats:p>Pulmonary hypertension (PH) commonly affects patients with systemic sclerosis (SSc) and is associated with significant morbidity and increased mortality. PH is a heterogenous condition and several different forms can be associated with SSc, including pulmonary arterial hypertension (PAH) resulting from a pulmonary arterial vasculopathy, PH due to left heart disease and PH due to interstitial lung disease. The incidence of pulmonary veno-occlusive disease is also increased. Accurate and early diagnosis to allow optimal treatment is, therefore, essential. Recent changes to diagnostic haemodynamic criteria at the 6th World Symposium on Pulmonary Hypertension have resulted in therapeutic uncertainty regarding patients with borderline pulmonary haemodynamics. Furthermore, the optimal pulmonary vascular resistance threshold for diagnosing PAH and the role of exercise in identifying early disease require further elucidation. In this article we review the epidemiology, diagnosis, outcomes and treatment of the spectrum of pulmonary vascular phenotypes associated with SSc.<\/jats:p>","DOI":"10.1183\/16000617.0053-2021","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T03:01:05Z","timestamp":1629255665000},"page":"210053","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":85,"title":["Pulmonary hypertension phenotypes in patients with systemic sclerosis"],"prefix":"10.1183","volume":"30","author":[{"given":"Ashraful","family":"Haque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0184-6502","authenticated-orcid":false,"given":"David G.","family":"Kiely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0717-4551","authenticated-orcid":false,"given":"A.A. Roger","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3492-4143","authenticated-orcid":false,"given":"Robin","family":"Condliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"key":"2024102403562260000_30.161.210053.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30933-9"},{"key":"2024102403562260000_30.161.210053.2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-018-8718-8","article-title":"Antinuclear antibodies in systemic sclerosis: an update","volume":"58","author":"Stochmal","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"2024102403562260000_30.161.210053.3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/rheumatology\/kex504","article-title":"Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis","volume":"57","author":"Distler","year":"2018","journal-title":"Rheumatol"},{"key":"2024102403562260000_30.161.210053.4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2028"},{"key":"2024102403562260000_30.161.210053.5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01913-2018"},{"key":"2024102403562260000_30.161.210053.6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"2024102403562260000_30.161.210053.7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200912-1820OC"},{"key":"2024102403562260000_30.161.210053.8","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/cvr\/cvx145","article-title":"RV pressure overload: from hypertrophy to failure","volume":"113","author":"Van Der Bruggen","year":"2017","journal-title":"Cardiovasc Res"},{"key":"2024102403562260000_30.161.210053.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.38029"},{"key":"2024102403562260000_30.161.210053.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.34501"},{"key":"2024102403562260000_30.161.210053.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2006.11.022"},{"key":"2024102403562260000_30.161.210053.12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1183\/09031936.00106008","article-title":"Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy","volume":"34","author":"Overbeek","year":"2008","journal-title":"Eur Respir J"},{"key":"2024102403562260000_30.161.210053.13","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/acr.22673","article-title":"Risk of pulmonary embolism and deep venous thrombosis in systemic sclerosis: a general population-based study","volume":"68","author":"Schoenfeld","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2024102403562260000_30.161.210053.14","unstructured":"Hatano S , Strasser T , World Health Organization . Primary Pulmonary Hypertension: Report on a WHO meeting. Geneva, World Health Organization, 1975."},{"key":"2024102403562260000_30.161.210053.15","unstructured":"Rich S . Primary Pulmonary Hypertension: Executive Summary from the World Symposium \u2013 Primary Pulmonary Hypertension 1998. http:\/\/www.wsphassociation.org\/wp-content\/uploads\/2019\/04\/Primary-Pulmonary-Hypertension-Evian-1998.pdf"},{"key":"2024102403562260000_30.161.210053.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.02.032"},{"key":"2024102403562260000_30.161.210053.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.011"},{"key":"2024102403562260000_30.161.210053.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.008"},{"key":"2024102403562260000_30.161.210053.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.032"},{"key":"2024102403562260000_30.161.210053.20","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01897-2018"},{"key":"2024102403562260000_30.161.210053.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.033"},{"key":"2024102403562260000_30.161.210053.22","first-page":"35","article-title":"Chronic cor pulmonale. Report of an expert committee","volume":"213","year":"1961","journal-title":"World Health Organ Tech Rep Ser"},{"key":"2024102403562260000_30.161.210053.23","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00145608"},{"key":"2024102403562260000_30.161.210053.24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.020207"},{"key":"2024102403562260000_30.161.210053.25","doi-asserted-by":"crossref","first-page":"e009729","DOI":"10.1161\/JAHA.118.009729","article-title":"Mild pulmonary hypertension is associated with increased mortality: a systematic review and meta-analysis","volume":"7","author":"Kolte","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2024102403562260000_30.161.210053.26","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00885-2017"},{"key":"2024102403562260000_30.161.210053.27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100245"},{"key":"2024102403562260000_30.161.210053.28","doi-asserted-by":"crossref","first-page":"102713","DOI":"10.1016\/j.autrev.2020.102713","article-title":"The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: systematic review and meta-analysis","volume":"20","author":"Rubio-Rivas","year":"2021","journal-title":"Autoimmun Rev"},{"key":"2024102403562260000_30.161.210053.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.24525"},{"key":"2024102403562260000_30.161.210053.30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.10.989"},{"key":"2024102403562260000_30.161.210053.31","doi-asserted-by":"publisher","DOI":"10.1378\/chest.123.2.344"},{"key":"2024102403562260000_30.161.210053.32","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0260"},{"key":"2024102403562260000_30.161.210053.33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200265"},{"key":"2024102403562260000_30.161.210053.34","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00078411"},{"key":"2024102403562260000_30.161.210053.35","doi-asserted-by":"publisher","DOI":"10.1002\/art.22069"},{"key":"2024102403562260000_30.161.210053.36","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/resp.12899","article-title":"Long-term outcomes of domiciliary intravenous iloprost in idiopathic and connective tissue disease-associated pulmonary arterial hypertension","volume":"22","author":"Ramjug","year":"2017","journal-title":"Respirology"},{"key":"2024102403562260000_30.161.210053.37","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.chest.2017.02.010","article-title":"Idiopathic and systemic sclerosis-associated pulmonary arterial hypertension: a comparison of demographic, hemodynamic, and MRI characteristics and outcomes","volume":"152","author":"Ramjug","year":"2017","journal-title":"Chest"},{"key":"2024102403562260000_30.161.210053.38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-011-0226-2","article-title":"An update on the evaluation and management of pulmonary hypertension in scleroderma","volume":"14","author":"Coghlan","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"2024102403562260000_30.161.210053.39","doi-asserted-by":"crossref","first-page":"6","DOI":"10.12703\/P7-06","article-title":"Connective tissue disease-associated pulmonary arterial hypertension","volume":"7","author":"Condliffe","year":"2015","journal-title":"F1000Prime Rep"},{"key":"2024102403562260000_30.161.210053.40","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00081009"},{"key":"2024102403562260000_30.161.210053.41","doi-asserted-by":"crossref","first-page":"604615","DOI":"10.1155\/2010\/604615","article-title":"Characteristics of interstitial fibrosis and inflammatory cell infiltration in right ventricles of systemic sclerosis-associated pulmonary arterial hypertension","volume":"2010","author":"Overbeek","year":"2010","journal-title":"Int J Rheumatol"},{"key":"2024102403562260000_30.161.210053.42","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.112.000008"},{"key":"2024102403562260000_30.161.210053.43","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00074309"},{"key":"2024102403562260000_30.161.210053.44","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.033147"},{"key":"2024102403562260000_30.161.210053.45","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.006974"},{"key":"2024102403562260000_30.161.210053.46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/bph.15016","article-title":"Current and future treatments of pulmonary arterial hypertension","volume":"178","author":"Sommer","year":"2021","journal-title":"Br J Pharmacol"},{"key":"2024102403562260000_30.161.210053.47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050010"},{"key":"2024102403562260000_30.161.210053.48","first-page":"2417","article-title":"Sildenafil for pulmonary arterial hypertension associated with connective tissue disease","volume":"34","author":"Badesch","year":"2007","journal-title":"J Rheumatol"},{"key":"2024102403562260000_30.161.210053.49","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.839274"},{"key":"2024102403562260000_30.161.210053.50","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijcard.2017.02.094","article-title":"Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease","volume":"235","author":"Gali\u00e8","year":"2017","journal-title":"Int J Cardiol"},{"key":"2024102403562260000_30.161.210053.51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209655"},{"key":"2024102403562260000_30.161.210053.52","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-209087"},{"key":"2024102403562260000_30.161.210053.53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012212"},{"key":"2024102403562260000_30.161.210053.54","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210236"},{"key":"2024102403562260000_30.161.210053.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413687"},{"key":"2024102403562260000_30.161.210053.56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213917"},{"key":"2024102403562260000_30.161.210053.57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602013340504"},{"key":"2024102403562260000_30.161.210053.58","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"2024102403562260000_30.161.210053.59","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.6.2106079"},{"key":"2024102403562260000_30.161.210053.60","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.2.420"},{"key":"2024102403562260000_30.161.210053.61","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02493-2016"},{"key":"2024102403562260000_30.161.210053.62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503184"},{"key":"2024102403562260000_30.161.210053.63","first-page":"837","article-title":"Long-term outcomes in patients with connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era: meta-analyses of randomized, controlled trials and observational registries","volume":"73","author":"Khanna","year":"2021","journal-title":"Br J Pharmacol"},{"key":"2024102403562260000_30.161.210053.64","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201507-1456OC"},{"key":"2024102403562260000_30.161.210053.65","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081277"},{"key":"2024102403562260000_30.161.210053.66","doi-asserted-by":"publisher","DOI":"10.1002\/art.30541"},{"key":"2024102403562260000_30.161.210053.67","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12931-019-1180-1","article-title":"Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension","volume":"20","author":"White","year":"2019","journal-title":"Respir Res"},{"key":"2024102403562260000_30.161.210053.68","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00495-2018"},{"key":"2024102403562260000_30.161.210053.69","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203301"},{"key":"2024102403562260000_30.161.210053.70","doi-asserted-by":"crossref","first-page":"R193","DOI":"10.1186\/ar4383","article-title":"The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study","volume":"15","author":"Thakkar","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2024102403562260000_30.161.210053.71","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13075-015-0517-5","article-title":"A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis","volume":"17","author":"Hao","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2024102403562260000_30.161.210053.72","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0023-2019"},{"key":"2024102403562260000_30.161.210053.73","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/rheumatology\/kex435","article-title":"Frequencies of borderline pulmonary hypertension before and after the DETECT algorithm: results from a prospective systemic sclerosis cohort","volume":"57","author":"Hoffmann-Vold","year":"2018","journal-title":"Rheumatol (Oxford)"},{"key":"2024102403562260000_30.161.210053.74","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00586-2019"},{"key":"2024102403562260000_30.161.210053.75","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01278-2019"},{"key":"2024102403562260000_30.161.210053.76","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/annrheumdis-2019-216476","article-title":"Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension","volume":"79","author":"Xanthouli","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024102403562260000_30.161.210053.77","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00008611"},{"key":"2024102403562260000_30.161.210053.78","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S2213-2600(20)30317-9","article-title":"Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study","volume":"8","author":"Maron","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024102403562260000_30.161.210053.79","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01654-2019"},{"key":"2024102403562260000_30.161.210053.80","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200546"},{"key":"2024102403562260000_30.161.210053.81","doi-asserted-by":"publisher","DOI":"10.1002\/art.37838"},{"key":"2024102403562260000_30.161.210053.82","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-014-0493-1"},{"key":"2024102403562260000_30.161.210053.83","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01197-2017"},{"key":"2024102403562260000_30.161.210053.84","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/art.40814","article-title":"Reduced right ventricular output reserve in patients with systemic sclerosis and mildly elevated pulmonary artery pressure","volume":"71","author":"Nagel","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024102403562260000_30.161.210053.85","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ejhf.1570","article-title":"Mildly increased pulmonary arterial pressure: a new disease entity or just a marker of poor prognosis?","volume":"21","author":"Kovacs","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2024102403562260000_30.161.210053.86","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01708-2016"},{"key":"2024102403562260000_30.161.210053.87","doi-asserted-by":"publisher","DOI":"10.1378\/chest.15-0125"},{"key":"2024102403562260000_30.161.210053.88","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.198"},{"key":"2024102403562260000_30.161.210053.89","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00021915"},{"key":"2024102403562260000_30.161.210053.90","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200806-953OC"},{"key":"2024102403562260000_30.161.210053.91","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00990-2016"},{"key":"2024102403562260000_30.161.210053.92","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2020.08.2110","article-title":"Exercise pulmonary resistances predict long-term survival in systemic sclerosis","volume":"159","author":"Zeder","year":"2021","journal-title":"Chest"},{"key":"2024102403562260000_30.161.210053.93","doi-asserted-by":"publisher","DOI":"10.1002\/art.33460"},{"key":"2024102403562260000_30.161.210053.94","doi-asserted-by":"publisher","DOI":"10.1002\/art.34614"},{"key":"2024102403562260000_30.161.210053.95","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s13075-019-1981-0","article-title":"Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)","volume":"21","author":"Pan","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2024102403562260000_30.161.210053.96","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00026-2016"},{"key":"2024102403562260000_30.161.210053.97","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00090608"},{"key":"2024102403562260000_30.161.210053.98","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2844"},{"key":"2024102403562260000_30.161.210053.99","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.014207"},{"key":"2024102403562260000_30.161.210053.100","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00814-2015"},{"key":"2024102403562260000_30.161.210053.101","first-page":"2347","article-title":"Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension","volume":"33","author":"Johnson","year":"2006","journal-title":"J Rheumatol"},{"key":"2024102403562260000_30.161.210053.102","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jacc.2004.02.033","article-title":"Pathologic assessment of vasculopathies in pulmonary hypertension","volume":"16","author":"Pietra","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2024102403562260000_30.161.210053.103","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000209834.69972.e5"},{"key":"2024102403562260000_30.161.210053.104","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00168-2018"},{"key":"2024102403562260000_30.161.210053.105","doi-asserted-by":"publisher","DOI":"10.1378\/chest.118.6.1671"},{"key":"2024102403562260000_30.161.210053.106","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e31818193bb"},{"key":"2024102403562260000_30.161.210053.107","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.028351"},{"key":"2024102403562260000_30.161.210053.108","first-page":"882","article-title":"Primary myocardial disease in scleroderma \u2013 a comprehensive review of the literature to inform the UK Systemic Sclerosis Study Group cardiac working group","volume":"56","author":"Bissell","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"2024102403562260000_30.161.210053.109","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00296-016-3470-y","article-title":"Cardiac involvement in systemic sclerosis: differences between clinical subsets and influence on survival","volume":"37","author":"Fern\u00e1ndez-Codina","year":"2017","journal-title":"Rheumatol Int"},{"key":"2024102403562260000_30.161.210053.110","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.53.3.483"},{"key":"2024102403562260000_30.161.210053.111","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfp198"},{"key":"2024102403562260000_30.161.210053.112","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1093\/rheumatology\/kez658","article-title":"Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis","volume":"59","author":"De Luca","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"2024102403562260000_30.161.210053.113","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.semarthrit.2019.06.013","article-title":"T1 mapping cardiac magnetic resonance imaging frequently detects subclinical diffuse myocardial fibrosis in systemic sclerosis patients","volume":"50","author":"Poindron","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2024102403562260000_30.161.210053.114","doi-asserted-by":"publisher","DOI":"10.1186\/1532-429X-16-21"},{"key":"2024102403562260000_30.161.210053.115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.07.068"},{"key":"2024102403562260000_30.161.210053.116","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.103382"},{"key":"2024102403562260000_30.161.210053.117","doi-asserted-by":"publisher","DOI":"10.1177\/2047487318786315"},{"key":"2024102403562260000_30.161.210053.118","doi-asserted-by":"crossref","unstructured":"D'Alto M , Romeo E , Argiento P , et al. Hemodynamic changes after acute fluid loading in patients with systemic sclerosis without pulmonary hypertension. Pulm Circ 2019; 9: 2045894018816089.doi 10.1177\/2045894018816089","DOI":"10.1177\/2045894018816089"},{"key":"2024102403562260000_30.161.210053.119","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00091212"},{"key":"2024102403562260000_30.161.210053.120","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.113.000468"},{"key":"2024102403562260000_30.161.210053.121","doi-asserted-by":"crossref","first-page":"2045893218757404","DOI":"10.1177\/2045893218757404","article-title":"Changes in hemodynamic classification over time are common in systemic sclerosis-associated pulmonary hypertension: insights from the PHAROS cohort","volume":"8","author":"Lammi","year":"2018","journal-title":"Pulm Circ"},{"key":"2024102403562260000_30.161.210053.122","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21693\/1933-088X-19.1.6","article-title":"Modern right heart catheterization: beyond simple hemodynamics","volume":"19","author":"Bonno","year":"2020","journal-title":"Adv Pulm Hypertens"},{"key":"2024102403562260000_30.161.210053.123","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv512"},{"key":"2024102403562260000_30.161.210053.124","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/2045893217700438","article-title":"Poor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fraction","volume":"7","author":"Bourji","year":"2017","journal-title":"Pulm Circ"},{"key":"2024102403562260000_30.161.210053.125","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv336"},{"key":"2024102403562260000_30.161.210053.126","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.983866"},{"key":"2024102403562260000_30.161.210053.127","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.001458"},{"key":"2024102403562260000_30.161.210053.128","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01886-2017"},{"key":"2024102403562260000_30.161.210053.129","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/art.40862","article-title":"Prevalence, treatment, and outcomes of coexistent pulmonary hypertension and interstitial lung disease in systemic sclerosis","volume":"71","author":"Young","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024102403562260000_30.161.210053.130","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2322031223"},{"key":"2024102403562260000_30.161.210053.131","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.resinv.2016.05.004","article-title":"A retrospective cohort study of outcome in systemic sclerosis-associated interstitial lung disease","volume":"54","author":"Okamoto","year":"2016","journal-title":"Respir Investig"},{"key":"2024102403562260000_30.161.210053.132","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2169\/internalmedicine.48.1714","article-title":"Nonspecific interstitial pneumonia associated with collagen vascular disease: analysis of CT features to distinguish the various types","volume":"48","author":"Daimon","year":"2009","journal-title":"Intern Med"},{"key":"2024102403562260000_30.161.210053.133","doi-asserted-by":"crossref","first-page":"322","DOI":"10.5606\/ArchRheumatol.2018.6630","article-title":"Clinical characteristics of systemic sclerosis with interstitial lung disease","volume":"33","author":"Jung","year":"2018","journal-title":"Arch Rheumatol"},{"key":"2024102403562260000_30.161.210053.134","doi-asserted-by":"publisher","DOI":"10.1002\/art.11073"},{"key":"2024102403562260000_30.161.210053.135","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024102403562260000_30.161.210053.136","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1046\/j.1523-1747.2003.12028.x","article-title":"The prevalence and clinical significance of anti-U1 RNA antibodies in patients with systemic sclerosis","volume":"120","author":"Asano","year":"2003","journal-title":"J Invest Dermatol"},{"key":"2024102403562260000_30.161.210053.137","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200706-877OC"},{"key":"2024102403562260000_30.161.210053.138","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/art.41512","article-title":"Hemodynamic response to treatment and outcomes in pulmonary hypertension associated with interstitial lung disease versus pulmonary arterial hypertension in systemic sclerosis: data from a study identifying prognostic factors in pulmonary hypertension associated with interstitial lung disease","volume":"73","author":"Chauvelot","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024102403562260000_30.161.210053.139","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-2473"},{"key":"2024102403562260000_30.161.210053.140","doi-asserted-by":"publisher","DOI":"10.1002\/art.24267"},{"key":"2024102403562260000_30.161.210053.141","doi-asserted-by":"crossref","first-page":"e0197112","DOI":"10.1371\/journal.pone.0197112","article-title":"Clinical phenotypes and survival of precapillary pulmonary hypertension in systemic sclerosis","volume":"13","author":"Launay","year":"2018","journal-title":"PLoS One"},{"key":"2024102403562260000_30.161.210053.142","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/art.39528","article-title":"Combined pulmonary fibrosis and emphysema in scleroderma-related lung disease has a major confounding effect on lung physiology and screening for pulmonary hypertension","volume":"68","author":"Antoniou","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2024102403562260000_30.161.210053.143","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00021005"},{"key":"2024102403562260000_30.161.210053.144","doi-asserted-by":"publisher","DOI":"10.1002\/art.30423"},{"key":"2024102403562260000_30.161.210053.145","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201403-0446OC"},{"key":"2024102403562260000_30.161.210053.146","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-9-201305070-00003"},{"key":"2024102403562260000_30.161.210053.147","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S2213-2600(19)30250-4","article-title":"Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study","volume":"7","author":"Nathan","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2024102403562260000_30.161.210053.148","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008470"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0053-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:05:22Z","timestamp":1740355522000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0053-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":148,"journal-issue":{"issue":"161","published-online":{"date-parts":[[2021,8,17]]},"published-print":{"date-parts":[[2021,9,30]]}},"alternative-id":["10.1183\/16000617.0053-2021"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0053-2021","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,17]]}}}